PT3423076T - Formulações tópicas contendo ciclosporina e respetivas utilizações - Google Patents

Formulações tópicas contendo ciclosporina e respetivas utilizações

Info

Publication number
PT3423076T
PT3423076T PT177606431T PT17760643T PT3423076T PT 3423076 T PT3423076 T PT 3423076T PT 177606431 T PT177606431 T PT 177606431T PT 17760643 T PT17760643 T PT 17760643T PT 3423076 T PT3423076 T PT 3423076T
Authority
PT
Portugal
Prior art keywords
containing formulations
topical cyclosporine
cyclosporine
topical
formulations
Prior art date
Application number
PT177606431T
Other languages
English (en)
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59744365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3423076(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of PT3423076T publication Critical patent/PT3423076T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT177606431T 2016-02-29 2017-02-28 Formulações tópicas contendo ciclosporina e respetivas utilizações PT3423076T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662301576P 2016-02-29 2016-02-29
US201662302058P 2016-03-01 2016-03-01
US201662302730P 2016-03-02 2016-03-02
US201662311177P 2016-03-21 2016-03-21

Publications (1)

Publication Number Publication Date
PT3423076T true PT3423076T (pt) 2024-07-01

Family

ID=59744365

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177606431T PT3423076T (pt) 2016-02-29 2017-02-28 Formulações tópicas contendo ciclosporina e respetivas utilizações

Country Status (21)

Country Link
US (4) US10918694B2 (pt)
EP (2) EP4410312A2 (pt)
JP (2) JP7072517B2 (pt)
KR (1) KR20180117661A (pt)
CN (1) CN109843316A (pt)
AU (2) AU2017227585C1 (pt)
BR (1) BR112018067946A8 (pt)
CA (1) CA3015626A1 (pt)
DK (1) DK3423076T3 (pt)
ES (1) ES2981702T3 (pt)
FI (1) FI3423076T3 (pt)
IL (1) IL268056A (pt)
MX (1) MX2018010395A (pt)
NZ (1) NZ755442A (pt)
PL (1) PL3423076T3 (pt)
PT (1) PT3423076T (pt)
RU (1) RU2747455C2 (pt)
SA (1) SA519410114B1 (pt)
SG (1) SG11201906729RA (pt)
WO (1) WO2017151657A1 (pt)
ZA (1) ZA201904704B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050298A1 (en) 2012-08-24 2014-02-27 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20190231885A1 (en) 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
CN109843316A (zh) 2016-02-29 2019-06-04 太阳制药全球公司 含有环孢菌素的局部制剂及其用途
CN112957450A (zh) * 2019-12-20 2021-06-15 艾棣维欣(苏州)生物制药有限公司 一种难溶性药物的水溶液及其制备方法
JP2024521968A (ja) 2021-06-14 2024-06-04 サン ファーマシューティカル インダストリーズ リミテッド 白内障手術を受ける患者において使用するための、シクロスポリン製剤
JP2024530244A (ja) 2021-08-20 2024-08-16 サン ファーマシューティカル インダストリーズ リミテッド 安定なシクロスポリン眼科用製剤及びその製造プロセス
WO2024042550A1 (en) * 2022-08-25 2024-02-29 Sentiss Pharma Private Limited Ophthalmic combination composition
WO2024098043A2 (en) * 2022-11-04 2024-05-10 Qlaris Bio, Inc. Topical ocular delivery of cromakalim

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023010A1 (en) * 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
JP2005506990A (ja) 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
WO2004069181A2 (en) 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US20090209599A1 (en) 2005-06-09 2009-08-20 Yoko Endo Eye drop containing roflumilast
CN102772358A (zh) 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
JPWO2007126110A1 (ja) 2006-04-24 2009-09-17 ナノキャリア株式会社 低分子薬物内包ポリマーミセルの製造方法
JPWO2007136134A1 (ja) 2006-05-23 2009-10-01 ナノキャリア株式会社 疎水性薬物内包ポリマーミセルの製造方法
WO2008010341A1 (fr) 2006-07-18 2008-01-24 Nanocarrier Co., Ltd. Polypeptide physiologiquement actif, micelle de polymère ayant une protéine enfermée dans celle-ci, et procédé d'obtention de la micelle de polymère
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
WO2009028674A1 (ja) 2007-08-29 2009-03-05 Wakamoto Pharmaceutical Co., Ltd. ラタノプロスト含有水性医薬組成物
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物
US20090286718A1 (en) * 2008-01-04 2009-11-19 Sirion Therapeutics, Inc. Stable Aqueous Cyclosporin Compositions
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
AU2009260572B2 (en) 2008-05-28 2015-07-23 Alcon Research, Ltd. Self-preserved emulsions
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20110040113A1 (en) 2009-06-02 2011-02-17 Nian Wu Pure PEG-lipid conjugates
CN102458370A (zh) 2009-06-09 2012-05-16 卢克斯生物科技公司 用于眼科用途的表面药物递送系统
EP2478906A4 (en) 2009-09-17 2013-02-20 Senju Pharma Co AQUEOUS OPHTHALMIC DROPS THAT CONTAIN LATANOPROST, AND A METHOD OF INHIBITING ADSORPTION OF LATANOPROST ON A RESIN
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2011138801A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
KR101211902B1 (ko) * 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
RU2014149993A (ru) 2012-05-11 2016-07-10 Сипла Лимитед Фармацевтическая композиция
CA3050298A1 (en) * 2012-08-24 2014-02-27 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
JP2017519813A (ja) 2014-05-23 2017-07-20 オキュラー テクノロジーズ エスアーエールエル 局所製剤およびその使用
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
US20190231885A1 (en) 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
EP3373924A4 (en) 2015-11-12 2019-06-19 Sun Pharma Global FZE TOPICAL FORMULATIONS AND USES THEREOF
CN109843316A (zh) 2016-02-29 2019-06-04 太阳制药全球公司 含有环孢菌素的局部制剂及其用途
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
NZ755442A (en) 2023-04-28
AU2017227585A1 (en) 2018-10-18
US20190060397A1 (en) 2019-02-28
US10918694B2 (en) 2021-02-16
ZA201904704B (en) 2022-10-26
DK3423076T3 (da) 2024-07-08
RU2019130403A (ru) 2021-03-26
MX2018010395A (es) 2018-11-29
SA519410114B1 (ar) 2024-02-11
BR112018067946A8 (pt) 2022-11-08
EP3423076B1 (en) 2024-04-17
JP2022110054A (ja) 2022-07-28
AU2017227585C1 (en) 2022-05-26
JP7547411B2 (ja) 2024-09-09
WO2017151657A1 (en) 2017-09-08
RU2747455C2 (ru) 2021-05-05
US20230083458A1 (en) 2023-03-16
US11951153B2 (en) 2024-04-09
ES2981702T3 (es) 2024-10-10
KR20180117661A (ko) 2018-10-29
AU2017227585B2 (en) 2022-02-17
US20240197818A1 (en) 2024-06-20
FI3423076T3 (fi) 2024-06-24
BR112018067946A2 (pt) 2019-01-15
IL268056A (en) 2019-08-29
RU2019130403A3 (pt) 2021-03-26
PL3423076T3 (pl) 2024-08-19
JP7072517B2 (ja) 2022-05-20
EP3423076A4 (en) 2019-11-27
EP3423076A1 (en) 2019-01-09
EP4410312A2 (en) 2024-08-07
US20210145924A1 (en) 2021-05-20
SG11201906729RA (en) 2019-08-27
CN109843316A (zh) 2019-06-04
JP2019507154A (ja) 2019-03-14
AU2022203135A1 (en) 2022-06-02
CA3015626A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
HK1248526A1 (zh) 包含大麻萜酚的化妝品和局部施用組合物
ZA201805805B (en) Formulations and methods
ZA201904704B (en) Topical cyclosporine-containing formulations and uses thereof
EP3303379A4 (en) TIGIT-BINDING ACTIVE SUBSTANCES AND USES THEREOF
EP3253890A4 (en) Tnfrsf-binding agents and uses thereof
EP3324967A4 (en) PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
HK1231376A1 (zh) 局部製劑及其應用
EP3191114A4 (en) Occidiofungin formulations and uses thereof
HUE056401T2 (hu) Topikális készítmények és kezelések
IL268583A (en) Preparations and methods for use on the skin
SG11201706938XA (en) Topical formulation
GB201608762D0 (en) Compositions and uses thereof
EP3373924A4 (en) TOPICAL FORMULATIONS AND USES THEREOF
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
PL3373976T3 (pl) Preparaty do stosowania miejscowego i ich zastosowanie
EP3525767A4 (en) TOPICAL FORMULATIONS AND TREATMENTS
GB201614897D0 (en) Compositions and uses thereof
GB201602409D0 (en) Compositions and uses thereof
GB201520755D0 (en) Nanoparticle formulations and their uses
IL265251A (en) Compositions of sealing material and their uses
GB201716745D0 (en) New formulations and uses thereof
IL248576A0 (en) Anti-lice preparation and its uses
GB201619949D0 (en) nOMV-antigen conjugated compounds and use thereof
AU2016902150A0 (en) Formulations and therapeutic uses thereof
GB201602398D0 (en) Compositions and uses thereof